Publications found:
50,876
Sort by:
AMGN - Old is Gold = Value Buy!
US$ 140.00
... philosophy to pursue “innovation” in a balanced way should keep shareholders interested in AMGN for long term. PhIII data from study ‘147 published ... more detail, please read our report released on 25th November on AMGN titled “AMGN - Old is Gold = Value Buy!”
November 2011
4 pages
Vertex – “Testing Time Ahead for INCIVEK - After 2013!”
US$ 140.00
... in 2014, would result in declining sales for INCIVEK/IFN combination. Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients ... read our report released on 25th November, 2011 on VRTX titled “Testing Time Ahead for INCIVEK - After 2013!”
November 2011
10 pages
US Glucose Monitoring Market Analysis
US$ 1,000.00
The US has a dominant share in the global diabetes market with 90-95% of the diabetic patients in the country suffering from type-II diabetes. Factors like, high prevalence of diabetes, rising aging p...
November 2011
55 pages
US Denim Jeans Market Report: 2011 Edition
US$ 700.00
... Old Navy are the topmost women’s denim brands in the US. The report analyzes the denim jeans industry in the US. Market trends like introduction of new concepts ...
November 2011
34 pages
US Pharmacy Benefit Management (PBM) Industry Report: 2011 Edition
US$ 800.00
... chronic condition has also risen. The report analyzes the US Pharmacy Benefit Management Industry. Rising drug prices, increasing drug utilization and prevalence ... , contracts for renewals of the major players and market share of PBM companies adjusted on the basis of acquisitions and contract shifts. This ...
November 2011
40 pages
PHARMASSET - "IFN-free Oral Option" for HCV- Sharing the Big Pie!
US$ 140.00
Pharmasset (VRUS) may enjoy the first mover advantage in the race to offer the first “IFN free all oral option” to HCV pts. However the window ... read our report released on Nov. 16th, 2011 on VRUS titled “IFN-free Oral Option” for HCV- Sharing the Big Pie!
November 2011
9 pages
BIOGEN IDEC - Data of BG-12 + Sales Growth Brighten 2012 Prospects
US$ 140.00
Biogen Idec (BIIB) is closing 2011 with a positive note and ... Copaxone (L, RRMS) share of the MS market. Moreover, PhIIb data readouts from SELECT trial of Daclizumab HYP (PhII, IL-2 alpha subunit ... read our report, released on Nov. 8, 2011 on “Biogen Idec - Data of BG-12 + Sales Growth Brighten 2012 Prospects”
November 2011
6 pages
Mature Biotech: 3Q11 Earnings Summary
US$ 90.00
In this note we summarize the 3Q earnings of Mature Biotech – ALXN, AMGN, BIIB, CELG, GILD, and ONXX. We continue to reiterate ... PhIII data in mCRC). For more details, please read our 3Q11 earnings’ summary report released on 4th Nov, 2011 on “Mature Biotech: 3Q11 Earnings Summary”.
November 2011
5 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
... ) wave to treat HCV the race to offer the first “IFN free all oral option” seems to have begun. Preliminary data from Abbott’s PhII trial ... ’11 is challenging Pharmasset (VRUS) multiprong approach. For more details, please read our report released on Oct. 24th, 2011 on VRUS titled “IFN-free Oral Option” for ...
October 2011
4 pages
US Medical Imaging Devices Market
US$ 1,000.00
The US has a dominant share in the global medical imaging devices industry. Commercialization of advanced systems, including multi-slice computer tomography (CT), high field magnetic resonance imaging...
October 2011
55 pages
The US AIDS Diagnostics Market: Test Volumes, Sales Forecasts, and Supplier Shares
US$ 1,480.00
Summary This report presents a detailed analysis of the US AIDS diagnostics market, including test volume and sales forecasts for HIV-1/2, HIV ... , Western Blot and other confirmatory tests performed in the following market segments: Hospitals Commercial/Private Laboratories Blood Banks Physician Offices ...
October 2011
251 pages
Gastrointestinal (GI) Endoscopy Devices: Market Research Report
US$ 4,500.00
This report analyzes the US market for Gastrointestinal (GI) Endoscopy Devices in US$ Million by the following Product Segments: GI Videoscopes (Video Colonoscopes, Video Gastroscopes, Video Duodenoscopes, Video Ultrasound Endoscopes, & Others (Includes Video Sigmoidoscope & Video Enteroscope)), Endoscopic ...
October 2011
284 pages
2012 U.S. Radio TV Broadcast Equipment Report
US$ 149.00
The Radio TV Broadcast Equipment report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2012 current and 2013 f...
October 2011
171 pages
Opportunities in the US Aerospace and MRO market: 2011-2016, October 2011
US$ 3,400.00
... features of “Opportunities in US Aerospace and MRO Market 2011 - 2016” include these: Market size estimates in terms of dollar value and number of units delivered in various ... (2005– –2010) and forecast (2011–2016) for US aerospace MRO market Growth opportunities in US aerospace industry Benefits of Lucintel Report: Lucintel’s core competency is in market ...
October 2011
86 pages
US Wine Market Outlook 2014
US$ 900.00
The US wine industry has been growing at a fast pace over the past few years, and has established a niche place in the global market. With a total contribution of 7.5% in global wine production, the U...
September 2011
75 pages
US Food Processing Machinery Market
US$ 1,000.00
Manufacturers of food processing machineries are facing a rapidly changing and highly demanding competitive environment. The food, beverage, pharmaceuticals, and personal care industries that purchase...
September 2011
45 pages
State of the Industry: Asian Restaurants in the U.S.
US$ 129.00
Note: Formats of Delivery: Word and ExcelPDF upon request State of the Industry reports are concise, yet detailed studies filled with priceless data, forecasts, and objective analysis. The amount of...
September 2011
-
The US Orthopedics Market: Strategic Assessments of Leading Suppliers
US$ 7,600.00
The report provides a strategic overview of the US orthopedics market, including forecasts for major market segments and product categories. In addition, the report presents a concise review of the major trends with potentially significant impact on the US ...
September 2011
620 pages
Vertex - Near Term Positive Long Term Neutral
US$ 140.00
... therapy area is heating up, Vertex (VRTX) will continue to have the edge for at least 3yrs. We expect most of the near term milestones related for ... read our report released on 23th September, 2011 on VRTX titled “Near Term Positive Long Term Neutral”.
September 2011
5 pages
Therapeutic Apheresis: Market Research Report
US$ 4,500.00
This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Photopheresis, Plasmapheresis, Erythrocytapheresis, Plateletpheresis, Leukapheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, ...
September 2011
126 pages
Direct-To-Consumer (DTC) Advertising in Pharmaceuticals: Market Research Report
US$ 4,200.00
This report analyzes the US market for Direct-To-Consumer (DTC) Advertising in Pharmaceuticals in US$ Million by the following media channels - Internet Advertising, Print Media, Television, and Others (include Outdoor and Radio Advertising). Annual estimates and forecasts are provided for the period 2009 ...
September 2011
577 pages
Pharmasset - Tapping Both IFN and IFN-Free Opportunities
US$ 140.00
... daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises ... NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the ... IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled “Tapping Both IFN and IFN ...
September 2011
7 pages
ALEXION - Great Expectations From Label Expansion
US$ 140.00
We have a positive expectation for the approval of Eculizumab (L, Soliris, Paroxysmal Nocturnal Hemoglobinuria) in Atypical ... more details, please read our report released on September 16, 2011 on Alexion (ALXN), titled “Great Expectations From Label Expansion”.
September 2011
4 pages
ARQULE - Read-Out Only in 2013
US$ 140.00
... . It is an attractive acquisition target due to…. For more details, please read our report released on 13th September, 2011 on ARQL titled “Read-Out Only in 2013”.
September 2011
4 pages
PHARMASSET - Another Step Towards Success!
US$ 90.00
Pharmasset (VRUS) announced top line data of PSI-7977 PhIIb, PROTON ... read our report released on 13th September, 2011 on VRUS titled “Another Step Towards Success”.
September 2011
4 pages
ARDEA - Entering the Pivotal Phase
US$ 140.00
After a long wait, Ardea (RDEA) reached an agreement with the FDA on the proposed PhIII ... in the report released on 12th September, 2011 on RDEA titled “Entering the Pivotal Phase”. For more details please ask for our initiation ...
September 2011
3 pages
State of the Industry: Book Stores in the U.S.
US$ 129.00
Note: Formats of Delivery: Word and ExcelPDF upon request State of the Industry reports are concise, yet detailed studies filled with priceless data, forecasts, and objective analysis. The amount of...
August 2011
-
Gilead - Complera Approval - Positive Long Term Impact
US$ 90.00
Approval of Complera (GILD’s Truvada + Tibotec’s Edurant) reiterates GILD’s ... HIV infection. With the current economic turmoil, approval of once-daily Complera (formerly Fixed Dose Combination drug) impact may ... report released on 12th August, 2011, titled – “Complera Approval - Positive Long Term Impact”
August 2011
5 pages
Celgene - Global Share Gains Continue + Pipeline Potential
US$ 140.00
... all commercial metrics – global share and duration gains, continued expansion of market ... access through approvals and reimbursements in the US and international market, and noteworthy operating efficiency places Celgene ... – “Global Share Gains Continue + Pipeline Potential”.
August 2011
6 pages
US Analytical Instruments Market Forecast
US$ 1,000.00
Single User PDF Format: US$ 1,000.00 Multi-User License: US$ 1,500.00 Hard Copy: US$ 1,100.00 CD-ROM: US$ 1,100.00 The world has witnessed a strong pattern of demand for analytical instruments and au...
July 2011
70 pages
US e-health Market Analysis
US$ 1,000.00
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,500.00
Hard Copy: US$ 1,100.00
CD-ROM: US$ 1,100.00 The US represents one of the most developed healthcare markets global...
July 2011
75 pages
Americas Monthly LNG Trade & Price Database, 2010
US$ 3,500.00
Price: Hard Copy - US$ 3,750.00 Price: CD-ROM - US$ 3,750.00 Price: Electronic (e.g. PDF) - US$ 3,500.00 Price: Site Licence - US$ 7,000.00 Price: Enterprisewide - US$ 10,500.00 “Americas Monthly LNG...
July 2011
-
Regeneron - Entering the Commercial TRAP
US$ 140.00
... US next month (PDUFA: August, 20). What are the risks to its commercial success and future of REGN’s pipeline? A comprehensive analysis about the ...
July 2011
7 pages
A Big BiTE - ALL Next!
US$ 140.00
... ) are favorable and increases our confidence in the potential of MITI’s BiTE (Bispecific T-Cell Engager) technology platform for developing better therapeutic ... please read our note released on 12th July on MITI titled “A Big BiTE - ALL Next”. With this purchase please inquire the discount on our ...
July 2011
5 pages
Mixed CARE-MS I data – Good for BIIB!
US$ 90.00
... (EDSS) was not achieved (vs. reduction of 91% in PhII data at 36 months) in its pivotal PhIII trial – CARE-MS I. What does this bode for other players ... ? Please read our report, released on 11th July, 2011, titled – “Mixed CARE-MS I data – Good for BIIB!”
July 2011
4 pages
